Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.056
+0.036 (3.53%)
Sep 2, 2026, 5:16 PM CET
Diamyd Medical AB Market Cap
Diamyd Medical AB has a market cap or net worth of 163.66 million as of September 2, 2026. Its market cap has decreased by -90.03% in one year.
Market Cap
163.66M
Enterprise Value
-182.44M
Revenue
432.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
1.06
ChartMarket Cap Chart
Since May 20, 2013, Diamyd Medical AB's market cap has increased from 132.51M to 163.66M, an increase of 23.51%. That is a compound annual growth rate of 1.60%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 2, 2026 | 163.66M | -89.43% |
| Dec 30, 2025 | 1.55B | -9.52% |
| Dec 30, 2024 | 1.71B | 182.47% |
| Dec 29, 2023 | 605.80M | -41.10% |
| Dec 30, 2022 | 1.03B | -9.66% |
| Dec 30, 2021 | 1.14B | -46.65% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 195.75M |
| Elicera Therapeutics AB | 182.19M |
| Abera Bioscience AB | 163.17M |
| Alzinova AB | 162.11M |
| Initiator Pharma | 160.18M |
| Xintela AB | 142.11M |
| Active Biotech AB | 134.97M |
| Simris Group AB (PUBL) | 134.17M |